用胎儿肺成熟度的羊水分析,在选择性中断妊娠、重复剖腹产前以及妊娠合并内科病时,正确估计分娩时间。本文目的是报导肺成熟度羊水试验的临床应用及其可靠程度。肺成熟度试验在预测新生儿呼吸困难综合症(简称RDS)时最有用。在美国,广泛应用此试验前,RDS每年几乎影响40,000个新生儿。本病死亡占30%左右,并有长期神经系统或肺部后遗症的危险。1957年Clements证实呼气时抗肺泡萎缩是由于降低表面张力的“表面活性剂”存在。它是在肺泡Ⅱ型细胞中产生,分泌到肺泡中。在动物与人,表面活性剂都必须在某个胎龄才能获得。在低水平时,婴儿可发生RDS,与早产 With amniotic fluid analysis of fetal lung maturity, the timing of childbirth is correctly estimated at the time of selective interruption of pregnancy, repeated caesarean section, and medical complications during pregnancy. The purpose of this paper is to report the clinical use of lung maturation amniotic fluid test and its reliability. Lung maturity test is most useful in predicting neonatal respiratory distress syndrome (RDS). In the United States, RDS affects almost 40,000 newborns annually until the trial is widely used. The death of this disease accounts for about 30%, and the risk of long-term nervous system or lung sequelae. Clements in 1957 demonstrated that anti-alveolar collapse during expiration was due to the presence of a “surfactant” that reduced the surface tension. It is produced in alveolar Type II cells and secreted into the alveoli. In animals and humans, surfactants must be obtained at a certain gestational age. At low levels, infants can develop RDS, with preterm birth